Remed Co

Remed Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of Remed Co (302550.KQ) as of Nov 19, 2026 is 0.07. In the previous year, Long-Term Debt to Equity Ratio was 0.13 — a change of -49.42% (lower).

LT Debt/Equity

0.07

YoY

-49.42%

Last updated:

Long-Term Debt to Equity Ratio of Remed Co is 2025 0.07 . Long-Term Debt to Equity Ratio of Remed Co was 2024 0.13 . It decreases by -49.42% lower compared to the previous year.

The Remed Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.60 KRW
Jan 1, 2019
0.24 KRW
Jan 1, 2020
0.63 KRW
Jan 1, 2021
0.63 KRW
Jan 1, 2022
0.10 KRW
Jan 1, 2023
0.13 KRW
Jan 1, 2024
0.13 KRW
Jan 1, 2025
0.07 KRW
The Remed Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.07-49.42%
0.13+3.90%
0.13+33.70%
0.10-84.71%
0.63-0.91%
0.63+166.04%
0.24-60.66%
0.60-40.21%
1.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Long-Term Debt to Equity Ratio of Remed Co is 0.07 in 2025.

Long-Term Debt to Equity Ratio of Remed Co changed from 0.13 to 0.07, representing a -49.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Remed Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Remed Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Remed Co

All Key Metrics — Remed Co